Differences in left ventricular diastolic dysfunction between eccentric and concentric left ventricular hypertrophy in hypertensive patients with preserved systolic function

Journal of International Medical Research

Volumn 39, Issue 3, 2011, Pages 772-779

  Masugata, H ^a   Senda, S ^a   Inukai, M ^a   Murao, K ^a   Hosomi, N ^b   Iwado, Y ^a   Noma, T ^a   Kohno, M ^a   Himoto, T ^a   Goda, F ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Echocardiography; Hypertension; Left ventricular diastolic dysfunction; Left ventricular hypertrophy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT;

ADULT; AGED; ARTICLE; BODY SURFACE; CARDIOVASCULAR PARAMETERS; CONCENTRIC LEFT VENTRICULAR HYPERTROPHY; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; ECCENTRIC LEFT VENTRICULAR HYPERTROPHY; ECHOCARDIOGRAPHY; FEMALE; FLOW RATE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PEAK EARLY DIASTOLIC MITRAL ANNULAR VELOCITY; PEAK EARLY TRANSMITRAL FLOW VELOCITY; PEAK LATE TRANSMITRAL FLOW VELOCITY;

EID: 80052186619     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900309     Document Type: Article

References (30)

1. Casale PN, Devereux RB, Milner M, et al: Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-178.
2. Levy D, Garrison RJ, Savage DD, et al: Prognostic implications of echocardio -graphically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
3. Verdecchia P, Schillaci G, Borgioni C, et al: Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48-54.
4. Diamond JA, Phillips RA: Hypertensive heart disease. Hypertens Res 2005; 28: 191-202.
5. Schillaci G, Pasqualini L, Verdecchia P, et al: Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002; 39: 2005-2011.
6. Redfield MM, Jacobsen SJ, Burnett JC Jr, et al: Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289: 194-202.
7. Nakamura T, Nakajima T, Suzuki N, et al: Left ventricular stiffness and chamber geometry in the pressure-overloaded hypertrophied heart. Tohoku J Exp Med 1976; 119: 245-256.
8. Karthikeyan VJ, Lip GY: Matrix metalloproteinases and hypertension: a link between left ventricular hypertrophy and diastolic dysfunction? Tohoku J Exp Med 2006; 208: 93-97.
9. Saglam M, Karakaya O, Esen AM, et al: Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects. Tohoku J Exp Med 2006; 208: 117-122.
10. Lang RM, Bierig M, Devereux RB, et al: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18: 1440-1463.
11. Ganau A, Devereux RB, Roman MJ, et al: Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992; 19: 1550-1558.
12. Teichholz LE, Kreulen T, Herman MV, et al: Problems in echocardiographic volume determinations: echocardiographicangiographic correlations in the presence of absence of asynergy. Am J Cardiol 1976; 37: 7-11.
13. Nishimura RA, Appleton CP: ''Diastology'': beyond E and A. J Am Coll Cardiol 1996; 27: 372-374.
14. Nishimura RA, Tajik AJ: Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography is the clinician's Rosetta Stone. J Am Coll Cardiol 1997; 30: 8-18.
15. Sohn DW, Chai IH, Lee DJ, et al: Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997; 30: 474-480.
16. Ommen SR, Nishimura RA, Appleton CP, et al: Clinical utility of Doppler chocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Dopplercatheterization study. Circulation 2000; 102: 1788-1794.
17. Nikitin NP, Witte KK: Application of tissue Doppler imaging in cardiology. Cardiology 2004; 101: 170-184.
18. Nagueh SF, Middleton KJ, Kopelen HA, et al: Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures. J Am Coll Cardiol 1997; 30: 1527-1533.
19. Cho IJ, Pyun WB, Shin GJ: The influence of the left ventricular geometry on the left atrial size and left ventricular filling pressure in hypertensive patients, as assessed by echocardiography. Korean Circ J 2009; 39: 145-150.
20. Mizuguchi Y, Oishi Y, Miyoshi H, et al: Concentric left ventricular hypertrophy brings deterioration of systolic longitudinal, circumferential, and radial myocardial deformation in hypertensive patients with preserved left ventricular pump function. J Cardiol 2010; 55: 23-33.
21. Verdecchia P, Carini G, Circo A, et al: Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 38: 1829-1835.
22. Yakabe K, Ikeda S, Naito T, et al: Left ventricular mass and global function in essential hypertension after antihypertensive therapy. J Int Med Res 2000; 28: 9-19.
23. Gosse P: Left ventricular hypertrophy-the problem and possible solutions. J Int Med Res 2005; 33(suppl 1): 3A-11A.
24. Verdecchia P: Pre-clinical and clinical experience of telmisartan in cardiac remodelling. J Int Med Res 2005; 33(suppl 1): 12A-20A.
25. Petrovic I, Petrovic D, Vukovic N, et al: Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005; 33(suppl 1): 39A-49A.
26. Anderson C: Rationale and design of the cardiac magnetic resonance imaging substudy of the ONTARGET Trial Programme. J Int Med Res 2005; 33(suppl 1): 50A-57A.
27. Sharp AS, Tapp RJ, Thom SA, et al: Tissue Doppler E/E′ ratio is a powerful predictor of primary cardiac events in a hypertensive population: an ASCOT substudy. Eur Heart J 2010; 31: 747-752.
28. Mullens W, Borowski AG, Curtin RJ, et al: Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure. Circulation 2009; 119: 62-70.
29. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105: 1387-1393.
30. Owan TE, Hodge DO, Herges RM, et al: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006; 355: 251-259.